Epizyme's Cancer Drug to Get Rapid FDA Review for a New Indication

Oncologists may soon have another weapon at their disposal in the fight against advanced follicular lymphoma, a type of cancer in need of new treatment options. The Food and Drug Administration has accepted Epizyme's (NASDAQ: EPZM) application to review tazemetostat for use by patients with that form of cancer.

Tazemetostat is an epigenetic therapy that targets EZH2-activating mutations by inhibiting chromatin-modifying proteins, or CMPs, that regulate chromatin, a complex comprising DNA and histone proteins responsible for gene expression. In January, the FDA approved it for use in advanced epithelioid sarcoma patients under the brand name Tazverik following a unanimous vote of support from the agency's advisory committee.

IMAGE SOURCE: GETTY IMAGES.

Source Fool.com